The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global psoriatic arthritis treatment market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Psoriatic arthritis is an autoimmune disorder wherein the immune system attacks the joints and causes inflammation. Its treatment options vary from oral medications that reduce swelling and inflammation to biological therapies that target the specific immune system. It is treated as per the level of pain, swelling, and stiffness. At present, key players are introducing new treatment methods that help prevent disease progression, reduce pain, protect joints, and preserve the range of motion. These methods can be combined with physical therapy to strengthen muscles and joints and increase overall stability.
Psoriasis disease is one of the major risk factors for psoriatic arthritis. As a result, the increasing prevalence of psoriasis disease due to infection, stress, obesity, skin injuries, alcohol abuse, and vitamin deficiencies represents one of the primary factors influencing the market positively. Moreover, as psoriatic arthritis occurs most commonly among individuals between the ages of 30 and 50, the rising adult population worldwide is contributing to the market growth. Apart from this, children with psoriatic arthritis are more likely to develop uveitis that affects the middle layer of tissue in the eyewall. This, in confluence with the growing concerns among parents about the health of their children, is catalyzing the demand for psoriatic arthritis treatment across the globe. In addition, the rising awareness about the benefits of early diagnosis and treatment of psoriatic arthritis, such as preventing serious damages, is bolstering the market growth. Other factors, such as inflating disposable income of individuals, improvement in healthcare facilities, and the growing health awareness among individuals, are anticipated to drive the demand for novel psoriatic arthritis treatment to combat severe symptoms.
IMARC Group provides an analysis of the key trends in each sub-segment of the global psoriatic arthritis treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug type, type, route of administration and distribution channel.
Breakup by Drug Type:
Breakup by Type:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.
|Base Year of the Analysis||2020|
|Segment Coverage||Drug Type, Type, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at